Essential Pharma: bringing to patients the next generation of treatments for Neuroblastoma and beyond
Gyrus Insights London was focused on providing Gyrus investors with a detailed update on the next generation of treatments for Neuroblastoma and how Essential Pharma is building an international platform for acquiring and developing rare disease medical products
Key takeaways
- High-risk Neuroblastoma remains the most common solid tumour in childhood, with limited survival rates and high treatment toxicity.
- Patient perspectives highlight the urgent need for more effective and less harmful therapeutic options.
- Essential Pharma is strengthening its focus on rare diseases, advancing its first development-stage asset—an anti-GD2 antibody for high-risk Neuroblastoma.
- Building an international rare disease platform requires a balance of acquisition capabilities, scientific expertise, and operational execution.
- Collaboration between investors, clinicians, and patient advocates is key to accelerating innovation and patient access in rare diseases.
Gyrus Insights Milan | June 12, 2025
Gyrus Insights London provided Gyrus investors with a detailed update on the next generation of treatments for Neuroblastoma and showcased Essential Pharma’s strategy to build an international platform dedicated to acquiring and developing rare disease medical products.
Speakers: Robert Watson (Managing Partner, Gyrus Capital), Emma Johnson (CEO, Essential Pharma), Lee Morley (Chairman, Essential Pharma), Simon Ball (VP, Pre-Commercial Unit, Essential Pharma), Professor Andy Pearson (Retired Professor of Pediatric Oncology, Institute of Cancer Research & Royal Marsden Hospital London), and Nick Bird, MBE (Patient Advocate & Chair of Trustees, Solving Kids’ Cancer UK).